SurgRx

About SurgRx

SurgRx, Inc. operated as a medical technology firm focused on the development of advanced energy systems for surgical applications. Founded in 2002 and based in Redwood City, California, the company carved a niche in the surgical device market before its acquisition. The leadership included Dave Clapper as President & CEO and Dr. Rodney Perkins as Chairman of the Board.

The company's core business centered on its proprietary EnSeal® family of devices, an advanced bipolar tissue sealing system. This technology was developed to provide surgeons with a tool that combines high compression and controlled radio-frequency energy to reliably seal blood vessels and tissue bundles during surgical procedures. The EnSeal device, which received FDA clearance in 2003, was capable of sealing vessels up to 7mm in diameter, a significant feature for surgeons performing both open and minimally invasive operations. The system was designed to grasp, dissect, seal, and transect tissue, offering a multifunctional instrument for various surgical specialties, including gynecology, general surgery, and urology.

SurgRx's business model involved the development and sale of these specialized surgical instruments and the underlying energy platform to hospitals and surgical centers. The primary clients were surgeons seeking tools that could minimize blood loss and reduce procedure times. A key milestone for the company was securing 510(k) regulatory approval from the FDA, which permitted its commercialization in the United States.

In August 2008, Ethicon Endo-Surgery, a subsidiary of Johnson & Johnson, announced a definitive agreement to acquire SurgRx. The acquisition was completed in October 2008. This strategic move allowed Ethicon to integrate SurgRx's bipolar energy platform with its own HARMONIC® line of ultrasonic medical devices, thereby creating a more comprehensive advanced energy portfolio to address diverse surgical needs. The acquisition represented a successful exit for SurgRx and its investors, which included firms like Alta Partners, California Technology Ventures, and New Enterprise Associates.